US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
US5968502A
(en)
*
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US5641670A
(en)
*
|
1991-11-05 |
1997-06-24 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
DK0731845T3
(en)
*
|
1993-12-23 |
2003-10-20 |
Merck & Co Inc |
Homologous recombinant antibody expression system for murine cells
|
US6818220B1
(en)
|
1994-11-14 |
2004-11-16 |
Licentia Ltd. |
Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6737513B1
(en)
|
1996-06-07 |
2004-05-18 |
Icos Corporation |
Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
|
US7018627B1
(en)
|
1995-06-07 |
2006-03-28 |
Icos Corporation |
Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
|
US6498015B1
(en)
|
1995-06-07 |
2002-12-24 |
Icos Corporation |
Methods of identifying agents that modulate the binding between MDC and an MDC receptor
|
US7727761B2
(en)
|
1995-08-01 |
2010-06-01 |
Vegenics Limited |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US5965125A
(en)
|
1995-10-25 |
1999-10-12 |
Transkaryotic Therapies, Inc. |
Hybrid matrix implants and explants
|
US6419920B1
(en)
|
1995-10-25 |
2002-07-16 |
Trans Karyotic Therapies, Inc. |
Hybrid matrix implants and explants
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US5989914A
(en)
*
|
1996-06-03 |
1999-11-23 |
Universite Laval |
Integration cassette for improvement of transgenesis in eukaryotes
|
SG94355A1
(en)
|
1996-10-01 |
2003-02-18 |
Geron Corp |
Human telomerase catalytic subunit
|
ES2312179T3
(en)
|
1996-12-06 |
2009-02-16 |
Amgen Inc. |
COMBINED THERAPY USING AN IL-1 INHIBITOR FOR THE TREATMENT OF ILL-1 ILLNESSES.
|
US7125714B2
(en)
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
KR20010020375A
(en)
*
|
1997-04-30 |
2001-03-15 |
무레 미카엘 에프. |
In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
|
US5888809A
(en)
*
|
1997-05-01 |
1999-03-30 |
Icos Corporation |
Hamster EF-1α transcriptional regulatory DNA
|
US6172211B1
(en)
|
1997-07-11 |
2001-01-09 |
Boehringer Ingelheim International Gmbh |
Nucleic acid encoding tag7 polypeptide
|
TR200000140T2
(en)
|
1997-07-23 |
2000-05-22 |
Roche Diagnostics Gmbh |
Determination of human cell lines for human protein production by endogenic gene activity
|
PT1000154E
(en)
|
1997-07-23 |
2007-03-30 |
Roche Diagnostics Gmbh |
Identification of human cell lines for the production of human proteins by endogenous gene activation
|
US6391633B1
(en)
|
1997-07-23 |
2002-05-21 |
Roche Diagnostics Gmbh |
Production of erythropoietin by endogenous gene activation
|
US6548296B1
(en)
|
1997-07-23 |
2003-04-15 |
Roche Diagnostics Gmbh |
Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
|
JP2001511341A
(en)
*
|
1997-07-23 |
2001-08-14 |
ロシュ ダイアグノスティックス ゲーエムベーハー |
Production of human mutant proteins by homologous recombination in human cells
|
TR200000175T2
(en)
*
|
1997-07-23 |
2001-01-22 |
Roche Diagnostics Gmbh |
Preparation of erythropoietin with endogenic gene activation.
|
AU776280B2
(en)
*
|
1997-07-23 |
2004-09-02 |
Roche Diagnostics Gmbh |
Production of erythropoietin by endogenous gene activation
|
US7316923B1
(en)
|
1997-09-26 |
2008-01-08 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US6897066B1
(en)
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US5932465A
(en)
*
|
1997-10-16 |
1999-08-03 |
Icos Corporation |
Phosphodiesterase 8A
|
JP4441112B2
(en)
|
1997-11-03 |
2010-03-31 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
VEGI is an inhibitor of angiogenesis and tumor growth
|
AU757930B2
(en)
*
|
1997-12-01 |
2003-03-13 |
Roche Diagnostics Gmbh |
Optimization of cells for endogenous gene activation
|
CN1280309C
(en)
|
1997-12-03 |
2006-10-18 |
罗切诊断学有限公司 |
Erythropoietin with high specific activity
|
CA2321224A1
(en)
|
1998-02-23 |
1999-08-26 |
Icos Corporation |
Phosphodiesterase 10
|
AU3066699A
(en)
|
1998-03-03 |
1999-09-20 |
Johns Hopkins University, The |
Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
|
US6479256B1
(en)
|
1998-03-04 |
2002-11-12 |
Icos Corporation |
Lectomedin materials and methods
|
US6200951B1
(en)
|
1998-03-12 |
2001-03-13 |
Icos Corporation |
Chitinase chitin-binding fragments
|
EP1982990A1
(en)
|
1998-03-19 |
2008-10-22 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6541623B1
(en)
|
1998-04-03 |
2003-04-01 |
Hyseq, Inc. |
Interleukin—1 receptor antagonist and uses thereof
|
US6337072B1
(en)
|
1998-04-03 |
2002-01-08 |
Hyseq, Inc. |
Interleukin-1 receptor antagonist and recombinant production thereof
|
US6426191B1
(en)
|
1998-04-03 |
2002-07-30 |
Hyseq, Inc. |
Assays involving an IL-1 receptor antagonist
|
US6294655B1
(en)
|
1998-04-03 |
2001-09-25 |
Hyseq, Inc. |
Anti-interleukin-1 receptor antagonist antibodies and uses thereof
|
US6071691A
(en)
*
|
1998-04-27 |
2000-06-06 |
Oregon Health Science University |
Materials and methods for modulating differentiation
|
US6492138B1
(en)
|
1998-05-21 |
2002-12-10 |
Amgen Canada Inc. |
Polynucleotides encoding a novel SHC-binding protein
|
US6447771B1
(en)
|
1999-03-19 |
2002-09-10 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6387645B1
(en)
|
1998-07-16 |
2002-05-14 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6476211B1
(en)
|
1998-07-16 |
2002-11-05 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
MXPA01000481A
(en)
|
1998-07-16 |
2002-11-29 |
Hyseq Inc |
Methods and materials relating to novel cd39-like polypeptides.
|
DE19857609A1
(en)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Use of erythropoietin for the treatment of human cerebral ischemia
|
DK1139793T3
(en)
|
1998-12-23 |
2010-03-01 |
Sinai School Medicine |
Bitter taste response inhibitors
|
US6780977B1
(en)
|
1999-01-29 |
2004-08-24 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6899875B1
(en)
|
1999-01-29 |
2005-05-31 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6350447B1
(en)
|
1999-01-29 |
2002-02-26 |
Hyseq, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
WO2000049162A2
(en)
*
|
1999-02-19 |
2000-08-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6335013B1
(en)
|
1999-03-19 |
2002-01-01 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
WO2000077179A2
(en)
|
1999-06-16 |
2000-12-21 |
Icos Corporation |
Human poly(adp-ribose) polymerase 2 materials and methods
|
US6632665B1
(en)
|
1999-08-09 |
2003-10-14 |
Wake Forest University |
Human gene encoding 3′-5′ exonuclease
|
EP2030986A1
(en)
|
1999-09-29 |
2009-03-04 |
The General Hospital Corporation |
Polypeptide derivative of parathyroid hormone (PTH)
|
US6344549B1
(en)
|
1999-10-14 |
2002-02-05 |
Icos Corporation |
ATR-2 cell cycle checkpoint
|
EP1222273A2
(en)
|
1999-10-22 |
2002-07-17 |
PHARMACIA & UPJOHN COMPANY |
Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
|
US7314716B2
(en)
|
1999-11-19 |
2008-01-01 |
Mount Sinai School Of Medicine |
Gustducin γ subunit materials and methods
|
AU1647501A
(en)
|
1999-12-10 |
2001-06-18 |
Cytos Biotechnology Ag |
Replicon based activation of endogenous genes
|
US6635742B1
(en)
|
2000-01-25 |
2003-10-21 |
Nuvelo, Inc. |
Antibodies specific for semaphorin-like polypeptides
|
US6465620B1
(en)
|
2000-01-21 |
2002-10-15 |
Hyseq, Inc. |
Methods and materials relating to novel von Willebrand/Thrombospondin-like polypeptides and polynucleotides
|
US6586390B1
(en)
|
2000-01-21 |
2003-07-01 |
Hyseq, Inc. |
Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
|
EP1728862A1
(en)
|
2000-03-16 |
2006-12-06 |
Genetica, Inc. |
Methods and compositions for RNA interference
|
US20030084471A1
(en)
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
CA2747325A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001274894A1
(en)
|
2000-05-22 |
2001-12-03 |
Pharmacia And Upjohn Company |
Novel matrix metalloproteinases
|
US7259146B2
(en)
|
2000-05-26 |
2007-08-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
Neuroprotective peptides
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
AU2001271839A1
(en)
|
2000-07-05 |
2002-01-14 |
Pharmacia And Upjohn Company |
Human ion channels
|
GB0018876D0
(en)
|
2000-08-01 |
2000-09-20 |
Applied Research Systems |
Method of producing polypeptides
|
ATE497007T1
(en)
|
2000-08-25 |
2011-02-15 |
Basf Plant Science Gmbh |
POLYNUCLEOTIDES CODING FOR PRENYL PROTEASES FROM PLANT
|
US6787684B2
(en)
|
2000-10-16 |
2004-09-07 |
E. & J. Gallo Winery |
Lipoxygenase genes from Vitis vinifera
|
ATE505204T1
(en)
|
2000-12-20 |
2011-04-15 |
Hoffmann La Roche |
CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG)
|
KR100896971B1
(en)
|
2001-02-02 |
2009-05-14 |
오르토-맥네일 파마슈티칼, 인코퍼레이티드 |
Treatment of neurological dysfunction, including fructopyranose sulfamate and erythropoietin
|
EP1366058B1
(en)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US7803982B2
(en)
|
2001-04-20 |
2010-09-28 |
The Mount Sinai School Of Medicine Of New York University |
T1R3 transgenic animals, cells and related methods
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
NZ532988A
(en)
|
2001-11-28 |
2008-04-30 |
Ortho Mcneil Pharm Inc |
Erythropoietin dosing regimen for treating anemia
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
GB0200977D0
(en)
*
|
2002-01-17 |
2002-03-06 |
Lonza Biologics Plc |
Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
|
AU2003226960B2
(en)
|
2002-01-17 |
2007-11-22 |
Lonza Biologics Plc. |
Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
|
KR20110014661A
(en)
|
2002-02-07 |
2011-02-11 |
노보자임스 바이오파마 디케이 에이/에스 |
Albumin-Fusion Kunitz Domain Peptides
|
AU2003218045A1
(en)
|
2002-03-11 |
2003-09-29 |
Ortho Mcneil Pharmaceutical, Inc |
Methods for shp1 mediated neuroprotection
|
EP1531848A4
(en)
|
2002-06-10 |
2007-03-28 |
Vaccinex Inc |
GENE EXPRESSING DIFFERENTIAL FA IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDES
|
AU2003254016A1
(en)
|
2002-07-19 |
2004-02-09 |
Catholic Healthcare West |
Methods and compositions relating to chimeric nicotinic receptor subunits
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
CA2513251C
(en)
|
2003-01-14 |
2013-03-19 |
Dana-Farber Cancer Institute |
Cancer therapy sensitizer
|
WO2004071462A2
(en)
|
2003-02-12 |
2004-08-26 |
Johns Hopkins University |
Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
|
EP1639005B1
(en)
|
2003-06-27 |
2017-05-03 |
Monell Chemical Senses Center |
Taste receptors of the t1r family from domestic cat
|
AU2005247858A1
(en)
|
2004-04-14 |
2005-12-08 |
Monell Chemical Senses Center |
Taste receptors of the T1R family from domestic dog
|
AU2005240002B2
(en)
|
2004-04-23 |
2009-06-18 |
Zoetis Services Llc |
Cellular permissivity factor for viruses, and uses thereof
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
DK1797183T3
(en)
|
2004-09-02 |
2012-10-01 |
Univ Yale |
REGULATION OF ONCOGENES WITH MICRORNAS
|
US7785807B2
(en)
|
2004-12-13 |
2010-08-31 |
Monell Chemical Senses Center |
Voltage-gated, pH-sensitive anion channel and its novel splice variant involved in taste sensation
|
WO2007002528A1
(en)
|
2005-06-23 |
2007-01-04 |
Yale University |
Anti-aging micrornas
|
WO2007142667A2
(en)
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
CA2626852A1
(en)
|
2005-11-03 |
2007-05-18 |
Redpoint Bio Corporation |
High throughput screening assay for the trpm5 ion channel
|
DE102006004008A1
(en)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
|
CN101062407A
(en)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
Function of erythropoietin in the preventing and treating of retinal injury
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
WO2008013861A2
(en)
|
2006-07-27 |
2008-01-31 |
Redpoint Bio Corporation |
Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
|
WO2008019368A2
(en)
|
2006-08-07 |
2008-02-14 |
Teva Biopharmaceuticals Usa, Inc. |
Albumin-insulin fusion proteins
|
EP1900749A1
(en)
|
2006-09-12 |
2008-03-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells
|
WO2008114673A1
(en)
|
2007-03-15 |
2008-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
Method for production of polypeptide
|
KR101461659B1
(en)
|
2007-05-11 |
2014-11-17 |
토마스 제퍼슨 유니버시티 |
Methods of treatment and prevention of neurodegenerative diseases and disorders
|
AU2008251467B2
(en)
|
2007-05-11 |
2014-07-31 |
The Trustees Of The University Of Pennsylvania |
Methods of treatment of skin ulcers
|
US9931377B2
(en)
|
2007-06-27 |
2018-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cell expressing complexes of IL-15 and IL-15Ralpha
|
AR067536A1
(en)
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM
|
CL2008002053A1
(en)
|
2007-07-17 |
2009-05-22 |
Hoffmann La Roche |
Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method.
|
WO2009010107A1
(en)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
|
ES2567561T3
(en)
|
2007-07-27 |
2016-04-25 |
Universiteit Gent |
Permissive cells and their uses
|
JP5711966B2
(en)
|
2007-08-01 |
2015-05-07 |
ザ ジェネラル ホスピタル コーポレイション |
Screening methods using G protein-coupled receptors and related compositions
|
DK2186905T3
(en)
|
2007-08-07 |
2016-09-19 |
Chugai Pharmaceutical Co Ltd |
Method of Preparation of Heterogeneous Protein
|
US9802993B2
(en)
|
2007-10-15 |
2017-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexate
|
DK2213746T3
(en)
|
2007-10-24 |
2015-08-03 |
Chugai Pharmaceutical Co Ltd |
CELL FOR USE IN THE PREPARATION OF exogenous protein, AND MANUFACTURING METHOD THAT USE CELL
|
NZ586947A
(en)
|
2008-02-08 |
2012-11-30 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
GB0803076D0
(en)
|
2008-02-20 |
2008-03-26 |
Univ Ghent |
Mucosal Membrane Receptor and uses thereof
|
CN107022020A
(en)
|
2008-09-26 |
2017-08-08 |
Ambrx公司 |
The animal erythropoietin polypeptides and its purposes of modification
|
US8110185B2
(en)
|
2008-10-03 |
2012-02-07 |
St. Michael's Hospital |
Method for preventing and treating cardiovascular diseases with BRCA1
|
NZ603996A
(en)
|
2009-02-02 |
2014-03-28 |
Chromocell Corp |
Cells or cell lines that stably express a bitter taste receptor and methods of making them
|
WO2010123014A1
(en)
|
2009-04-22 |
2010-10-28 |
中外製薬株式会社 |
Method for preparing cell highly producing heterogeneous protein
|
EP2460006A2
(en)
|
2009-07-31 |
2012-06-06 |
Chromocell Corporation |
Methods and compositions for identifying and validating modulators of cell fate
|
CA2769651A1
(en)
|
2009-08-05 |
2011-02-10 |
Chromocell Corporation |
Improved plants, microbes, and organisms
|
EP2464661B1
(en)
|
2009-08-13 |
2018-01-17 |
The Johns Hopkins University |
Methods of modulating immune function with anti-b7-h7cr antibodies
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
BR112012028949B1
(en)
|
2010-05-13 |
2020-11-17 |
Chugai Seiyaku Kabushiki Kaisha |
parathyroid hormone analog polypeptide, its use and production method, as well as nucleic acid, expression vector, cell and pharmaceutical composition
|
JP5735650B2
(en)
|
2010-09-14 |
2015-06-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Method for purifying PEGylated erythropoietin
|
US20130224797A1
(en)
|
2010-10-15 |
2013-08-29 |
Jcr Pharmaceuticals Co., Ltd. |
Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
|
WO2012101671A1
(en)
|
2011-01-25 |
2012-08-02 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human recombinant iduronate 2-sulfatase
|
JP6219170B2
(en)
|
2011-02-07 |
2017-10-25 |
セレニス セラピューティクス ホールディング エスアー |
Lipoprotein complex and its production and use
|
CA2828811C
(en)
|
2011-03-03 |
2021-09-21 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
TWI674272B
(en)
|
2011-04-01 |
2019-10-11 |
中外製藥股份有限公司 |
Nucleic acid molecule with APES activity
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
WO2013009971A1
(en)
|
2011-07-12 |
2013-01-17 |
E. I. Du Pont De Nemours And Company |
Detection and screening method and materials useful in performance thereof
|
WO2013020044A1
(en)
|
2011-08-03 |
2013-02-07 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Treatment of fibrosis using microrna-19b
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
WO2014016873A1
(en)
|
2012-07-26 |
2014-01-30 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of recombinant human alpha-galactosidase a
|
US11608508B2
(en)
|
2012-10-10 |
2023-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method for establishing modified host cell
|
JP6359019B2
(en)
|
2012-10-24 |
2018-07-18 |
ノバルティス アーゲー |
IL-15Rα type, cells expressing IL-15Rα type, and therapeutic use of IL-15Rα and IL-15 / IL-15Rα complex
|
EP2970420A4
(en)
|
2013-03-15 |
2016-08-17 |
Apotex Inc |
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
WO2016018920A1
(en)
|
2014-07-29 |
2016-02-04 |
Admune Therapeutics Llc |
Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
|
KR102617137B1
(en)
|
2014-09-15 |
2023-12-27 |
칠드런'즈 메디컬 센터 코포레이션 |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
US10413597B2
(en)
|
2014-09-29 |
2019-09-17 |
Alexion Pharmaceuticals, Inc. |
Methods of treating Mucopolysaccharidosis IIIB (MPSIIIB)
|
US11191811B2
(en)
|
2014-11-19 |
2021-12-07 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
CA2874083C
(en)
|
2014-12-05 |
2024-01-02 |
Universite Laval |
Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
|
WO2016116966A1
(en)
|
2015-01-22 |
2016-07-28 |
Jcr Pharmaceuticals Co., Ltd. |
Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
|
SG11201811553UA
(en)
|
2016-07-15 |
2019-01-30 |
Hoffmann La Roche |
Method for purifying pegylated erythropoietin
|
EP3570870A1
(en)
|
2017-01-20 |
2019-11-27 |
Novartis AG |
Combination therapy for the treatment of cancer
|
CA3046120A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
CN111727063A
(en)
|
2017-12-29 |
2020-09-29 |
豪夫迈·罗氏有限公司 |
Methods for providing pegylated protein compositions
|
ES2905105T3
(en)
|
2017-12-29 |
2022-04-07 |
Hoffmann La Roche |
Procedure for Providing a PEGylated Protein Composition
|
WO2019129876A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Process for providing pegylated protein composition
|
EP3830261A1
(en)
*
|
2018-08-02 |
2021-06-09 |
Novozymes A/S |
Preparation of combinatorial libraries of dna constructs using introns
|
KR20220137651A
(en)
|
2020-02-05 |
2022-10-12 |
노파르티스 아게 |
CHO cells expressing IL-15 heterodimer
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
IL317448A
(en)
|
2022-06-10 |
2025-02-01 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
|
AU2023284357A1
(en)
|
2022-06-10 |
2025-01-23 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
WO2024129459A1
(en)
|
2022-12-16 |
2024-06-20 |
University Of Rochester |
Repairmen! of barrier dysfunction in esophagus
|